While present knowledge of HGF/c-MET has supported clinical trials targeting various aspects of the biological mechanism, more mature studies addressing side effects and clinical outcomes specific to pancreatic cancer are lacking. This evidence concerns the gene MET and familial pancreatic carcinoma.